Novavax earns $125 million as Sanofi dosing triggers flu-COVID vaccine trial milestone
Sanofi's Phase 3 trial combining its high-dose flu shot with Novavax's Nuvaxovid reached its fifth dosed patient, activating the payment.
SEC filing
Latest
Thursday, October 29
Perrigo to sell Infant Formula business to MeridianMade for up to $175 million
The deal, announced October 29, 2026, pays Perrigo $40 million upfront with up to $135 million more tied to milestones through 2030.
SEC filing
Rafael's Cyclo Therapeutics files NDA for remibetadex in Niemann-Pick Disease Type C
The October 28, 2026 filing seeks a rare pediatric priority review voucher and follows a Phase 3 study that missed its main goal but showed benefit in a prespecified subgroup.
Drugs@FDA, SEC filing (2)
Valion Bio reports clean safety data for Entolimod from AFRRI radiation study
The government-funded mouse study found no treatment-related toxicity, and Valion says the program can now move to a fully funded therapeutic efficacy study.
SEC filing
Azitra expands ATR-04 trial eligibility to KRAS, MEK inhibitor rash patients
The company broadened its Phase 1/2 study of ATR04-484 beyond EGFR inhibitor rash, adding cancer and NF1 patients and shortening washout periods to speed enrollment.
SEC filing (2)
Processa gets FDA clearance for VT-7208 Phase 2 in chronic hives, names new board chair
The company also added an FcRn antagonist program from Generian Pharmaceuticals and said cash should last into the second half of 2029.
SEC filing
INmune Bio prices $4.5 million offering, confirms Feb 2027 UK filing for RDEB therapy
Pricing of 3 million shares at $1.50 was announced October 28, 2026, a day after the company signed the purchase agreement, with closing expected October 29.
SEC filing (2)
Kymera reports positive KT-579 Phase 1 data, updates KT-621 and cash runway
Lupus trial for KT-579 set to start by early 2027 as Kymera reports topline AD data from KT-621 due by year-end 2026 and $1.6 billion cash into 2029.
SEC filing
Indivior reports record SUBLOCADE revenue ahead of Supernus merger close
Indivior posted record quarterly SUBLOCADE sales and adjusted EBITDA as its all-stock merger with Supernus heads toward a November 2, 2026 close.
SEC filing
Molecular Partners narrows focus to radiotherapy, plans workforce cuts
The company said emerging MP0712 data support a pivot to radiopharmaceuticals, with job cuts and a cash runway into late 2027.
SEC filing
Johns Hopkins-sponsored HCC trial of Nivolumab plus Relatlimab posts results, now not recruiting
Altimmune draws $10 million Tranche Three under Hercules Capital loan facility
Altimmune said it drew the funds on October 27, 2026 after meeting a milestone tied to its $125 million loan agreement, extending the interest-only period to June 1, 2028.
SEC filing
Amgen's MariTide cardiovascular outcomes trial surfaces; OASIS pediatric migraine results hold
AbbVie posts KEEPsAKE 2 update; registers pediatric vitiligo and real-world MIRV studies
Bristol Myers Squibb drops Prothena's PRX019 after internal review
BMS will not advance PRX019 in the clinic, ending a license tied to up to $617.5 million in potential milestones, Prothena said in an October 29, 2026 filing.
SEC filing
Celularity and Vesalius Longevity Labs sign exclusive peptide API manufacturing deal
The companies will build a U.S.-based finishing operation for Vesalius's Peptual-branded peptide ingredients at Celularity's New Jersey facility.
SEC filing
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filing
Merck reported $18.1 billion in third-quarter sales and detailed FDA approvals, a priority BLA filing for sac-TMT, and new guidance including one-time charges tied to the Cidara and Terns deals.
SEC filing (2)
Biohaven's Q3 update: FDA accepts Vyglxia filing, SK Biopharmaceuticals deal pending
Vyglxia resubmission for spinocerebellar ataxia carries a 1Q27 FDA goal date, while the SK Biopharmaceuticals license for opakalim awaits closing after HSR clearance.
SEC filing
BridgeBio reports Q3 2026 results, three PDUFA dates ahead and new Phase 3 study starts
BridgeBio dosed the first participants in the Phase 3b/4 ASCEND-ATTR study and the Phase 3 RECLAIM-HP study, while reporting $1.5 billion in cash as of September 30, 2026.
SEC filing
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's program
Alnylam reported $1,292 million in quarterly net product revenue, expanded its nucresiran Phase 3 study to 2,250 patients, and reported Phase 1 data for brezosiran in Huntington's disease.
SEC filing (2)
Propanc Biopharma gets Nasdaq bid price deficiency notice
Nasdaq told Propanc on October 23, 2026 that its stock had failed to maintain the $1.00 minimum bid price, putting the company's listing at risk unless it appeals by October 30.
SEC filing
Virax Biolabs signs three distributors for ImmuneSelect in mainland China
The company's China subsidiary struck non-exclusive deals with AmyJet, Jiangsu Real-Gen and Zhixi to sell its research-use immune profiling products across six provinces.
SEC filing
Ionetix grants stock options to executives and directors, adopts bonus plan
On October 23, 2026, Ionetix Corporation's Compensation Committee granted stock options to its CEO and CFO, adopted a non-employee director compensation plan, and approved an annual bonus plan for its subsidiary.
SEC filing
GlucoTrack to be delisted from Nasdaq after missing bid price deadline
Nasdaq will suspend trading in GlucoTrack's common stock on October 30, 2026, after the company failed to maintain a $1.00 closing bid price through its compliance deadline.
SEC filing
Phathom reports Q3 2026 results, advances VOQUEZNA pipeline and defends exclusivity
Phathom started a Phase 3 as-needed GERD trial, expects EoE Phase 2 data in Q4, and is fighting an exclusivity challenge, while reaffirming full-year guidance.
SEC filing
Kite registers new Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myeloma
BeOne Medicines adds Phase 1 trial of BG-92505, a KEAP1 activator, in solid tumors
PTC Therapeutics reports Q3 2026 results, raises revenue guidance, advances pipeline
PTC lifted its full-year revenue outlook on Sephience growth while reporting new timelines for its ST-920 gene therapy, votoplam and vatiquinone programs.
SEC filing
Bicycle Therapeutics reports Q3 2026 results, orphan drug status for nuzefatide in pancreatic cancer
The FDA designation and planned radioligand trial for BT1702 come as the company reports $469.9 million in cash and a runway into 2030.
SEC filing
Wednesday, October 28
Glucotrack files pro forma financials for completed Lokahi merger and reverse splits
The 8-K shows the combined company with $54.5 million in pro forma assets, $25.4 million in IPR&D, and a net loss widened by bridge financing charges.
SEC filing
Geron halts Phase 3 IMpactMF trial of imetelstat in myelofibrosis
An independent monitoring committee concluded the trial was unlikely to show an overall survival benefit, prompting Geron to end the study on October 28, 2026.
SEC filing
Par Health recalls argatroban injection lots over particulate contamination
Two Class I recalls cover nearly 21,000 vials of argatroban injection distributed nationwide after foreign particles were found in the solution.
FDA recall (2)
Greenwich Rx recalls glutathione injection over microbial contamination
The Class I recall covers 4,319 vials distributed nationwide after the firm identified microbial contamination of a sterile product.
FDA recall
Adial Pharmaceuticals becomes Azora Therapeutics, shifts to Nasdaq ticker AZR
Stockholders approved converting preferred stock from the June 2026 Azora merger, and the renamed company will advance AT177, an AhR agonist for ulcerative colitis, toward a 2027 Phase 1 trial.
SEC filing
Benitec reports positive interim high-dose BB-301 results, durable low-dose benefit in OPMD trial
Benitec Biopharma announced October 28, 2026 interim Phase 1b/2a data showing all nine treated OPMD patients across both BB-301 doses are formal responders, with high dose showing greater gains at three months.
SEC filing
Gain Therapeutics names Jeanette Weidner Vice President, Finance
The company said Weidner, effective October 28, 2026, will also serve as principal financial and accounting officer under a new employment agreement.
SEC filing
ClearPoint Neuro posts Q3 2026 revenue of $12.1 million, raises full-year outlook
The company said neurosurgery navigation and therapy revenue grew 59% on IRRAflow sales, and it raised 2026 revenue guidance to $48.0 million to $50.0 million.
SEC filing
Viking advances four Phase 3 obesity trials, reports positive VK2735 maintenance data
Viking said its SUNRISE oral Phase 3 trials for VK2735 have begun alongside the ongoing VANQUISH subcutaneous studies, while a maintenance-dosing readout showed durable weight loss with less frequent dosing.
SEC filing
TransCode retains Tungsten Advisors for strategic review of oncology portfolio
The company will explore licensing, partnership and other deals for lead candidate TTX-MC138 and its broader pipeline.
SEC filing
LENZ Therapeutics cuts 2027 budget, CEO to step down as VIZZ sales climb
LENZ reported 50% quarterly growth in VIZZ sales, a reorganization cutting headcount about 75%, and a CEO transition effective December 1, 2026.
SEC filing
GridAI advances $1.5 million more to Pronghorn, lifts note to $5 million
A fourth advance on October 22, 2026 brings GridAI's total loan to Pronghorn Resources to $5 million under a newly restated note maturing December 31, 2026.
SEC filing (2)
Bausch Health Companies Inc. files 8-K: results of operations
A record notice: the source is linked, and no summary was written because none passed the fact check.
SEC filing
DBV Technologies files BLA for Viaskin Peanut Patch in children 4-7, seeks priority review
The company reported third-quarter 2026 results, cash of $165.7 million, and a going concern warning tied to its runway into the third quarter of 2027.
SEC filing
Arcutis appoints Rob Scott, MD to board of directors
The commercial-stage dermatology company added the former AbbVie chief medical officer effective October 23, 2026, expanding its board to eleven members.
SEC filing
Vir Biotechnology adds Suzanne Topalian to board of directors
The company expanded its board from eight to nine members and named Dr. Topalian to fill the new seat and serve on its Science and Technology Committee.
SEC filing
MD Anderson registers Phase 1a/1b trial combining Jazz's zanidatamab with Boehringer's zongertinib i
Accufy Diagnostics discloses $2 million equity offering in SEC Form D filing
The Rockville, Maryland biotechnology company reported selling the full offering amount to three investors under a Rule 506(b) exemption.
SEC filing
Actuate Therapeutics closes $11.0 million public offering
The clinical-stage cancer drug developer sold shares and warrants, netting about $9.96 million after fees, with the deal closing October 28, 2026.
SEC filing
Vanda posts Q3 2026 results, cites NEREUS and HETLIOZ Phase III wins
Vanda reported positive Phase III data for NEREUS in GLP-1-induced vomiting and for HETLIOZ in sleep-wake disorder, alongside a pending Quimilza FDA decision and a Q4 BYSANTI launch.
SEC filing
Milestone Pharmaceuticals gets Nasdaq notice for low share price
The company has until April 21, 2027 to lift its share price back above $1.00 or face possible delisting from the Nasdaq Global Select Market.
SEC filing